Jan Dominik Kuhlmann

13PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 24, 2026
A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer.

|Feb 06, 2025
Methylstat sensitizes ovarian cancer cells to PARP-inhibition by targeting the histone demethylases JMJD1B/C.

Franziska Maria Schwarz, Daniel Martin Klotz, Ruming Yang

|Sep 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt

|Aug 12, 2023
Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer.

Daniel Martin Klotz, Franziska Maria Schwarz, Anna Dubrovska

|Aug 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.

Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer

Pageof 3